Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 6:11:732223.
doi: 10.3389/fcimb.2021.732223. eCollection 2021.

Antifungal Pipeline

Todd Patrick McCarty  1   2 , Peter G Pappas  1
Affiliations
Review

Antifungal Pipeline

Todd Patrick McCarty et al. Front Cell Infect Microbiol. .

Abstract

In many ways, fungal diseases are forgotten or neglected. Given the significantly lower frequency compared to similar bacterial etiologies across the spectrum of infectious syndromes, it makes sense that anti-bacterial agents have seen the bulk of development in recent decades. The vast majority of new antifungal medications approved for use in the past 10 years have been new versions in the same class as existing agents. Clinical mycology is crying out for new mechanisms of action in the setting of rising resistance and emergence of new organisms. Fortunately, this trend appears to be reversing. There are numerous agents in advanced stages of development offering novel dosing regimens and mechanisms of action to combat these threats. Herein we review seven antifungal agents that we hope to see come to market in the coming years to aid physicians in the treatment of mucocutaneous and invasive fungal infections.

Keywords: Candida; antifungal; antimicrobials; aspergillosis; fungal infections; mycology.

PubMed Disclaimer

Conflict of interest statement

TM - research grant support from Amplyx, Cidara; Consulting - T2Biosystems PP - Research support: Merck, Amplyx, Scynexis, Gilead, Astellas, Mayne, Cidara; Consulting, DRC: Matinas, Cidara, Mayne, Scynexis, Appili; Speakers bureau: None; Equities: None. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a shared consortium with one of the authors PP at time of review.

References

    1. Alexander B. D., Johnson M. D., Pfeiffer C. D., Jimenez-Ortigosa C., Catania J., Booker R., et al. . (2013). Increasing Echinocandin Resistance in Candida Glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations. Clin. Infect. Dis. 56 (12), 1724–1732. 10.1093/cid/cit136 - DOI - PMC - PubMed
    1. Alkhazraji S., Gebremariam T., Alqarihi A., Gu Y., Mamouei Z., Singh S., et al. . (2020). Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected With Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis. Antimicrob. Agents Chemother. 64 (3), e01735–19. 10.1128/AAC.01735-19 - DOI - PMC - PubMed
    1. Angulo D., Tufa M., Azie N. (2019). A Phase 2b, Dose-Selection Study Evaluating the Efficacy and Safety of Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE). Am. J. Obstet. Gynecol. 221 (6), 673. 10.1016/j.ajog.2019.10.088 - DOI
    1. Apgar J. M., Wilkening R. R., Parker D. L., Jr., Meng D., Wildonger K. J., Sperbeck D., et al. . (2021). Ibrexafungerp: An Orally Active Beta-1,3-Glucan Synthesis Inhibitor. Bioorg. Med. Chem. Lett. 32, 127661. 10.1016/j.bmcl.2020.127661 - DOI - PubMed
    1. Arendrup M. C., Chowdhary A., Astvad K. M. T., Jorgensen K. M. (2018. a). APX001A In Vitro Activity Against Contemporary Blood Isolates and Candida Auris Determined by the EUCAST Reference Method. Antimicrob. Agents Chemother. 62 (10), e01225–18. 10.1128/AAC.01225-18 - DOI - PMC - PubMed

MeSH terms